查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1929585

GalNAc-siRNA偶聯藥物市場按適應症、年齡層、應用類型、最終用戶和分銷管道分類，全球預測，2026-2032年

GalNAc-siRNA Conjugates Drug Market by Indication, Patient Age Group, Application Type, End User, Distribution Channel - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 192 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

GalNAc-siRNA偶聯藥物市場預計到2025年將達到11億美元，到2026年將成長到11.9億美元，到2032年將達到18.2億美元，年複合成長率為7.45%。

關鍵市場統計數據
基準年 2025 11億美元
預計年份：2026年 11.9億美元
預測年份 2032 18.2億美元
複合年成長率 (%) 7.45%

GalNAc-siRNA偶聯物的策略應用：科學原理、轉化研究進展及其對治療開發的基礎意義

GalNAc連接的siRNA療法代表了標靶基因靜默藥物發展的關鍵轉折點，它結合了受體介導的肝臟遞送和高效的序列特異性基因敲低。化學、遞送技術和改進的雙鏈設計之間的融合，使RNA干擾從實驗室現象轉變為以肝臟疾病為中心的實用治療方法。隨著學術發現逐漸轉化為臨床階段的藥物，藥物發現、臨床開發、生產和商業化領域的相關人員也調整了自身能力，以滿足寡核苷酸療法的獨特需求。

技術、監管先例和商業策略的關鍵變革性轉變將重新定義 GalNAc-siRNA 的開發和應用格局。

在科學技術的進步、監管標準的規範化以及商業模式的不斷發展的推動下，GalNAc-siRNA療法領域經歷了變革性的變化。配體-受體靶向化學的進步提高了肝細胞的攝取率，同時限制了全身暴露，從而降低了安全性不確定性並縮短了轉化週期。同時，研發人員正致力於最佳化雙股化學，以提高療效的持久性並降低給藥頻率，從而提高患者的依從性和醫保報銷的接受度。

2025年美國關稅調整對GalNAc-siRNA開發人員的採購、製造在地化和供應鏈彈性策略的影響

美國2025年宣布實施的關稅和貿易措施將對GalNAc-siRNA生態系統的供應鏈規劃、採購和生產經濟性產生重大影響。雖然治療藥物和活性藥物原料藥通常受益於特殊的貿易分類和協商豁免，但關稅表的變化將影響試劑、原料和支持寡核苷酸合成的專用設備的到岸成本。因此，各組織需要重新評估籌資策略和供應商契約，以降低投入成本波動的影響，同時確保產品品質和合規性。

深入的細分洞察，解釋了治療適應症、臨床環境、通路、患者人口統計特徵和應用類型如何驅動差異化的開發和商業化策略。

細分市場分析表明，每種疾病的治療、終端用戶環境、通路、患者群體和適應症類型都對研發和商業化策略提出了獨特的要求。就適應症而言，其範圍涵蓋代謝性疾病、腫瘤和罕見疾病，其中代謝性疾病又細分為高膽固醇症和第2型糖尿病，腫瘤疾病主要集中於肝癌，而罕見疾病則包括遺傳性轉甲狀腺素蛋白類澱粉沉積症和A型血友病這些臨床標靶決定了不同的臨床試驗設計、安全性監測框架和長期療效指標，因此計畫團隊需要將臨床前模型與特定適應症的終點指標相匹配。

深入分析美洲、歐洲、中東和非洲以及亞太地區的趨勢將如何影響臨床開發、生產策略和市場進入途徑的關鍵區域洞察

區域趨勢不斷影響著 GalNAc-siRNA 療法的臨床試驗設計、監管互動、製造地和商業化部署計畫。在美洲，完善的臨床試驗基礎設施和成熟的醫保報銷環境為快速招募受試者和盡早商業性提供了機遇，但也帶來了支付方的嚴格審查和對真實世界證據的高要求。同時，歐洲、中東和非洲地區 (EMEA)法規結構和市場進入途徑的多樣性，要求採用統一的證據包和區域客製化的衛生經濟模型，以最大限度地促進不同國家體系的採納。

主要企業洞察揭示了平台差異化、策略聯盟和智慧財產權策略如何塑造競爭優勢和交易結構。

GalNAc-siRNA領域各公司之間的競爭與合作行為揭示了其平台差異化和務實夥伴關係的雙重關注點。領先的研發公司強調穩健的遞送化學、檢驗的肝臟標靶化和可擴展的生產流程，而規模較小的創新者則致力於小眾適應症和新型化學方法的概念驗證。在整個生態系統中，合約開發和生產組織（CDMO）合作、戰略許可協議以及多學科研究合作正在迅速將臨床前研究成果轉化為臨床階段項目。

為行業領導者提供實用建議，以透過平台開發、供應鏈韌性、證據生成和商業模式調整來建立永續的競爭優勢。

治療藥物研發和商業化領域的領導者應採取一系列有針對性的措施，將科學潛力轉化為永續的市場地位。首先，在計畫設計早期就應納入給藥平台選擇和適應症優先排序，以確保試驗終點、生產計畫和支付方證據策略之間的無縫銜接。其次，透過多司法管轄區的合格以及與能夠擴大寡核苷酸生產規模並滿足監管品質要求的契約製造建立策略合作夥伴關係，確保生產和供應鏈的韌性。

透過透明且可重複的調查方法提供可靠的決策支持，這些方法結合了與關鍵相關人員的對話、二手文獻的綜合分析以及交叉檢驗的分析方法。

本研究整合了一手和二手訊息，建構了一套嚴謹透明的調查方法，優先考慮研究結果的可重複性和對決策的相關性。一手資訊來自對產業主管、臨床研究人員、監管專業人士、生產專家和支付方的結構化訪談，並輔以匿名化的研發專案案例研究，以了解實際挑戰及其應對策略。二手分析則納入了同行評審文獻、監管指南、臨床試驗註冊資訊、生產最佳實踐和專利趨勢，以驗證研究結果並檢驗主題趨勢。

簡潔的結論，整合了技術進步、監管現實和策略要務，以推動 GalNAc-siRNA 計畫從研發走向永續商業化。

總之，GalNAc-siRNA偶聯物處於引人注目的科學進展與實際商業化挑戰的交匯點，遞送化學的進步和監管政策的明確性正在為其帶來顯著的治療效果。平台能力的成熟催生了一種新的競爭動態，其特點是專注於平台差異化、策略夥伴關係以及確保生產韌性。同時，貿易政策的變化以及監管和報銷體系的區域差異等外部因素，要求企業制定適應性策略，以平衡全球目標與本地執行。

目錄

第1章：序言

第2章調查方法

  • 研究設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查前提
  • 調查限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會地圖
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

8. GalNAc-siRNA偶聯藥物市場依適應症分類

  • 代謝性疾病
    • 高膽固醇症
    • 2型糖尿病
  • 腫瘤學
  • 罕見疾病
    • Hatr類澱粉沉積症
    • A型血友病A

9. 依患者年齡層分類的 GalNAc-siRNA 偶聯藥物市場

  • 成人
  • 兒童

10. GalNAc-siRNA偶聯藥物市場（按應用領域分類）

  • 預防
  • 治療

11. GalNAc-siRNA偶聯藥物市場（按最終用戶分類）

  • 家庭醫療保健
  • 醫院
  • 研究所
  • 專科診所

12. GalNAc-siRNA偶聯藥物市場依分銷管道分類

  • 醫院藥房
  • 網路藥房
  • 零售藥房

13. GalNAc-siRNA偶聯藥物市場（按地區分類）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

14. GalNAc-siRNA偶聯藥物市場（依組別分類）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

15. 各國 GalNAc-siRNA 偶聯藥物市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

16. 美國 GalNAc-siRNA 偶聯藥物市場

17. 中國 GalNAc-siRNA 偶聯藥物市場

第18章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Akcea Therapeutics, Inc.
  • Alnylam Pharmaceuticals, Inc.
  • Arrowhead Pharmaceuticals, Inc.
  • AstraZeneca plc
  • BioNTech SE
  • CureVac NV
  • Dicerna Pharmaceuticals, Inc.
  • GlaxoSmithKline plc
  • Ionis Pharmaceuticals, Inc.
  • Moderna, Inc.
  • Novartis AG
  • Novo Nordisk A/S
  • Pfizer Inc.
  • Roche Holding AG
  • Sanofi SA
  • Sarepta Therapeutics, Inc.
  • Takeda Pharmaceutical Company Limited
Product Code: MRR-0A3806951834

The GalNAc-siRNA Conjugates Drug Market was valued at USD 1.10 billion in 2025 and is projected to grow to USD 1.19 billion in 2026, with a CAGR of 7.45%, reaching USD 1.82 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 1.10 billion
Estimated Year [2026] USD 1.19 billion
Forecast Year [2032] USD 1.82 billion
CAGR (%) 7.45%

A strategic introduction to GalNAc-siRNA conjugates clarifying scientific rationale, translational progress, and the foundational implications for therapeutic development

GalNAc-conjugated small interfering RNA therapeutics represent a decisive inflection point in the development of targeted gene silencing medicines, combining receptor-mediated hepatic delivery with potent, sequence-specific knockdown. The convergence of chemistry, delivery engineering, and improved duplex design has repositioned RNA interference from a laboratory phenomenon to a viable therapeutic modality for liver-centric indications. As academic discoveries matured into clinical-stage assets, stakeholders across discovery, clinical development, manufacturing, and commercialization have adapted their capabilities to contend with the distinct requirements of oligonucleotide therapeutics.

This introduction frames the scientific rationale and translational trajectory that underpin the GalNAc-siRNA field, clarifying how improvements in stability, reduced off-target effects, and predictable pharmacokinetics have driven a renewed interest among development-stage companies and established biopharmaceutical players. Furthermore, regulatory pathways and clinical precedent have begun to crystallize, enabling more consistent development strategies. In light of these developments, decision-makers need concise, actionable intelligence that connects molecular design choices to clinical endpoints and downstream commercial considerations. The subsequent sections synthesize technological shifts, policy influences, segmentation dynamics, regional differentiation, and corporate activity to provide a cohesive baseline for strategy formation and stakeholder dialogue.

Critical transformative shifts in technology, regulatory precedents, and commercial strategies that are redefining the GalNAc-siRNA development and deployment landscape

The landscape for GalNAc-siRNA therapeutics has undergone transformative shifts driven by scientific refinements, regulatory normalization, and evolving commercial models. Advances in ligand-receptor targeting chemistry have improved hepatocyte uptake while limiting systemic exposure, which in turn has reduced safety uncertainties and shortened translational timelines. Simultaneously, developers emphasize optimization of duplex chemistry to enhance durability of effect and reduce dosing frequency, thereby improving patient adherence potential and payer receptivity.

Regulatory and clinical precedents have reduced perceived execution risk, prompting new entrants to form strategic alliances with contract development and manufacturing organizations to secure scalable production capacity. In parallel, investment flows have diversified, with capital moving toward platform-enabled companies that demonstrate reproducible delivery and modular development pathways across multiple indications. Commercial models have also shifted: instead of one-off product launches, organizations are exploring portfolio-based approaches that leverage shared delivery platforms and centralized hepatic expertise. These dynamics collectively elevate the importance of integrated strategies that reconcile scientific differentiation with pragmatic commercialization planning, including pricing structures tied to clinical durability and real-world performance.

How United States tariff adjustments for 2025 will affect procurement, manufacturing localization, and supply chain resilience strategies for GalNAc-siRNA developers

The imposition of United States tariffs and trade measures announced for 2025 introduces a material variable for supply chain planning, procurement, and manufacturing economics within the GalNAc-siRNA ecosystem. Although therapeutics and active pharmaceutical ingredients often benefit from specialized trade classifications and negotiated exemptions, changes in tariff schedules influence the landed cost of reagents, raw materials, and specialized instrumentation that support oligonucleotide synthesis. Consequently, organizations must revisit sourcing strategies and supplier agreements to mitigate input cost volatility while preserving quality and regulatory compliance.

In response, many developers are reassessing localization of critical manufacturing steps and expanding qualified supplier networks across multiple jurisdictions to reduce exposure to single-country supply disruptions. Contract manufacturing partners are adapting by refining cost models, optimizing inventory buffers, and investing in modular capacity that can be shifted geographically. Additionally, procurement teams are increasingly incorporating tariff scenarios into supplier selection matrices and total cost of ownership analyses to ensure that commercial pricing, reimbursement discussions, and contract negotiations reflect realistic cost structures. Ultimately, a disciplined approach to supply chain resilience-encompassing dual sourcing, regional redundancy, and early supplier qualification-will prove essential for organizations operating in this evolving trade environment.

Deep segmentation insights explaining how therapeutic indications, care settings, distribution channels, patient age groups, and application types drive differentiated development and commercialization approaches

Segmentation insights reveal that therapeutic focus, end-user settings, distribution pathways, patient demographics, and application types each impose unique requirements on development and commercialization strategies. When considering indication, the field spans metabolic disorders, oncology, and rare diseases, with metabolic disorders subdivided to address hypercholesterolemia and type 2 diabetes, oncology concentrating on liver cancer, and rare diseases encompassing hereditary transthyretin amyloidosis and hemophilia A. These clinical targets dictate differing clinical trial designs, safety monitoring frameworks, and long-term outcome measures, requiring program teams to align preclinical models with indication-specific endpoints.

From an end-user perspective, delivery models must accommodate home healthcare administration, hospital-based infusion or outpatient dosing, research institute collaborations for early-stage trials, and specialty clinic management for chronic administration. Distribution channel differentiation across hospital pharmacies, online pharmacies, and retail pharmacies informs packaging, cold chain considerations, and patient support programs. Patient age group segmentation-split between adults and pediatric populations-further influences dosing strategies, safety margins, and caregiver engagement. Finally, application type separated into prophylaxis and treatment frames the value proposition, determining clinical trial duration, regulatory evidence expectations, and payer negotiation approaches. Integrating these segmentation dimensions into program strategy enables tailored development pathways that better reflect the clinical, operational, and commercial realities of each targeted use case.

Key regional insights into how Americas, Europe Middle East & Africa, and Asia-Pacific dynamics shape clinical development, manufacturing strategy, and market access pathways

Regional dynamics continuously shape clinical trial design, regulatory engagement, manufacturing footprint, and commercial roll-out plans for GalNAc-siRNA therapeutics. In the Americas, robust clinical trial infrastructure and a mature reimbursement environment create opportunities for accelerated trial enrollment and early commercial uptake, but also present intense payer scrutiny and elevated expectations for real-world evidence. Conversely, Europe, Middle East & Africa involves a mosaic of regulatory frameworks and market access pathways that require harmonized evidence packages and localized health economic models to maximize adoption across divergent national systems.

Asia-Pacific exhibits varied capabilities: certain markets offer rapid recruitment and cost-efficient manufacturing capacity, while others emphasize regulatory harmonization and expanded public health initiatives that can support broader access. These regional distinctions influence choices about where to site pivotal trials, how to structure manufacturing redundancy, and which market access value dossiers to prioritize. Consequently, strategic planning must account for differential clinical pathways, regional reimbursement sensitivities, intellectual property environments, and local partner selection criteria to ensure effective deployment across multiple geographies.

Key company insights revealing how platform differentiation, strategic partnerships, and intellectual property approaches are shaping competitive dynamics and deal structures

Competitive and collaborative behaviors among firms active in the GalNAc-siRNA space reveal a dual focus on platform differentiation and pragmatic partnerships. Leading developers emphasize robust delivery chemistry, validated hepatic targeting, and scalable manufacturing processes, while smaller innovators pursue niche indications or novel chemistries to demonstrate proof of concept. Across the ecosystem, alliances with contract development and manufacturing organizations, strategic licensing agreements, and cross-disciplinary research collaborations have accelerated the translation of preclinical findings into clinical-stage programs.

Moreover, intellectual property strategies center on delivery frameworks, sequence optimization, and manufacturing processes, prompting many organizations to pursue a balanced approach that combines defensive patenting with selective cross-licensing. Financial and operational partnerships often take the form of co-development agreements, milestone-linked licenses, and manufacturing capacity guarantees, which serve to distribute development risk and align incentives. Investors and corporate development teams are increasingly assessing partners based on platform robustness, regulatory experience, and supply chain resilience rather than short-term asset valuations, which reshapes how deals are structured and how projects progress from bench to bedside.

Actionable recommendations for industry leaders to align platform development, supply chain resilience, evidence generation, and commercial models for durable competitive advantage

Leaders in therapeutic development and commercialization should adopt a set of targeted actions to translate scientific promise into durable market positions. First, integrate delivery platform choices with indication prioritization early in program design so that trial endpoints, manufacturing plans, and payer evidence strategies align seamlessly. Second, secure manufacturing and supply chain resilience through multi-jurisdictional qualifications and strategic partnerships with contract manufacturing organizations that can scale oligonucleotide production while meeting regulatory quality expectations.

Third, pursue value-focused evidence generation that emphasizes durability of effect, safety profile clarity, and real-world outcomes to strengthen reimbursement discussions. Fourth, structure commercial models to reflect differentiated distribution needs across hospital pharmacies, online channels, and retail outlets while ensuring consistent patient support and adherence infrastructure for adult and pediatric populations. Finally, maintain flexible business development approaches that combine defensive intellectual property with collaborative licensing and co-development arrangements to accelerate access and broaden therapeutic reach. Implementing these actions will tighten the link between translational innovation and sustainable commercial execution.

A transparent and reproducible research methodology combining primary stakeholder engagement, secondary literature synthesis, and cross-validated analytical techniques for reliable decision support

This research synthesizes primary and secondary intelligence to produce a rigorous, transparent methodology designed for reproducibility and decision relevance. Primary insights derive from structured interviews with industry executives, clinical investigators, regulatory specialists, manufacturing experts, and payers, complemented by anonymized case studies from development programs to capture practical challenges and mitigation strategies. Secondary analysis incorporates peer-reviewed literature, regulatory guidance, clinical trial registries, manufacturing best practices, and patent landscapes to triangulate findings and validate thematic trends.

Analytical techniques emphasize qualitative synthesis with scenario testing and sensitivity analysis for supply chain and regulatory contingencies. Evidence was cross-validated through multiple stakeholder perspectives to minimize bias, and key assumptions were documented to preserve traceability. Where appropriate, methodological notes highlight inclusion criteria for clinical programs and manufacturing technologies, and validation checkpoints ensure that recommendations reflect current operational realities. This structured approach supports actionable conclusions while maintaining methodological openness for further inquiry and update.

A concise conclusion synthesizing technological progress, regulatory realities, and strategic imperatives to advance GalNAc-siRNA programs from development to durable commercialization

In conclusion, GalNAc-siRNA conjugates stand at the intersection of compelling scientific progress and practical commercialization challenges, with delivery chemistry advances and regulatory clarity creating pathways for meaningful therapeutic impact. The maturation of platform capabilities has fostered new competitive dynamics characterized by platform differentiation, strategic partnerships, and concentrated efforts to secure manufacturing resilience. At the same time, external forces such as trade policy shifts and regional heterogeneity in regulatory and reimbursement systems necessitate adaptive strategies that balance global ambition with local execution.

Taken together, these dynamics underscore the need for integrated planning that connects early-stage design choices to clinical evidence generation, supply chain architecture, and commercial model design. For stakeholders aiming to lead within this evolving field, the imperative is to translate technical advantages into repeatable, scalable programs that meet clinical, regulatory, and economic demands. With disciplined implementation of the insights and recommendations herein, organizations can better position their programs to deliver therapeutic value and achieve sustainable operational trajectories.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. GalNAc-siRNA Conjugates Drug Market, by Indication

  • 8.1. Metabolic Disorders
    • 8.1.1. Hypercholesterolemia
    • 8.1.2. Type 2 Diabetes
  • 8.2. Oncology
  • 8.3. Rare Diseases
    • 8.3.1. Hattr Amyloidosis
    • 8.3.2. Hemophilia A

9. GalNAc-siRNA Conjugates Drug Market, by Patient Age Group

  • 9.1. Adults
  • 9.2. Pediatric

10. GalNAc-siRNA Conjugates Drug Market, by Application Type

  • 10.1. Prophylaxis
  • 10.2. Treatment

11. GalNAc-siRNA Conjugates Drug Market, by End User

  • 11.1. Home Healthcare
  • 11.2. Hospitals
  • 11.3. Research Institutes
  • 11.4. Specialty Clinics

12. GalNAc-siRNA Conjugates Drug Market, by Distribution Channel

  • 12.1. Hospital Pharmacies
  • 12.2. Online Pharmacies
  • 12.3. Retail Pharmacies

13. GalNAc-siRNA Conjugates Drug Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. GalNAc-siRNA Conjugates Drug Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. GalNAc-siRNA Conjugates Drug Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. United States GalNAc-siRNA Conjugates Drug Market

17. China GalNAc-siRNA Conjugates Drug Market

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025
  • 18.5. Akcea Therapeutics, Inc.
  • 18.6. Alnylam Pharmaceuticals, Inc.
  • 18.7. Arrowhead Pharmaceuticals, Inc.
  • 18.8. AstraZeneca plc
  • 18.9. BioNTech SE
  • 18.10. CureVac N.V.
  • 18.11. Dicerna Pharmaceuticals, Inc.
  • 18.12. GlaxoSmithKline plc
  • 18.13. Ionis Pharmaceuticals, Inc.
  • 18.14. Moderna, Inc.
  • 18.15. Novartis AG
  • 18.16. Novo Nordisk A/S
  • 18.17. Pfizer Inc.
  • 18.18. Roche Holding AG
  • 18.19. Sanofi S.A.
  • 18.20. Sarepta Therapeutics, Inc.
  • 18.21. Takeda Pharmaceutical Company Limited

LIST OF FIGURES

  • FIGURE 1. GLOBAL GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL GALNAC-SIRNA CONJUGATES DRUG MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL GALNAC-SIRNA CONJUGATES DRUG MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY INDICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY PATIENT AGE GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY APPLICATION TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. UNITED STATES GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 13. CHINA GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY METABOLIC DISORDERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY METABOLIC DISORDERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY METABOLIC DISORDERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY METABOLIC DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY HYPERCHOLESTEROLEMIA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY HYPERCHOLESTEROLEMIA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY HYPERCHOLESTEROLEMIA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY TYPE 2 DIABETES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY TYPE 2 DIABETES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY TYPE 2 DIABETES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY ONCOLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY ONCOLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY RARE DISEASES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY RARE DISEASES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY RARE DISEASES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY RARE DISEASES, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY HATTR AMYLOIDOSIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY HATTR AMYLOIDOSIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY HATTR AMYLOIDOSIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY HEMOPHILIA A, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY HEMOPHILIA A, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY HEMOPHILIA A, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY ADULTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY ADULTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY ADULTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY PEDIATRIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY PEDIATRIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY PEDIATRIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY APPLICATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY PROPHYLAXIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY PROPHYLAXIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY PROPHYLAXIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY TREATMENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY TREATMENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY TREATMENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY HOME HEALTHCARE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY HOME HEALTHCARE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY HOME HEALTHCARE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY RESEARCH INSTITUTES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY RESEARCH INSTITUTES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY HOSPITAL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY HOSPITAL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY ONLINE PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 64. AMERICAS GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 65. AMERICAS GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 66. AMERICAS GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY METABOLIC DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 67. AMERICAS GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY RARE DISEASES, 2018-2032 (USD MILLION)
  • TABLE 68. AMERICAS GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 69. AMERICAS GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY APPLICATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 70. AMERICAS GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 71. AMERICAS GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 72. NORTH AMERICA GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 73. NORTH AMERICA GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 74. NORTH AMERICA GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY METABOLIC DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 75. NORTH AMERICA GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY RARE DISEASES, 2018-2032 (USD MILLION)
  • TABLE 76. NORTH AMERICA GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 77. NORTH AMERICA GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY APPLICATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 78. NORTH AMERICA GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 79. NORTH AMERICA GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 80. LATIN AMERICA GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 81. LATIN AMERICA GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 82. LATIN AMERICA GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY METABOLIC DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 83. LATIN AMERICA GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY RARE DISEASES, 2018-2032 (USD MILLION)
  • TABLE 84. LATIN AMERICA GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 85. LATIN AMERICA GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY APPLICATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 86. LATIN AMERICA GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 87. LATIN AMERICA GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 88. EUROPE, MIDDLE EAST & AFRICA GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 89. EUROPE, MIDDLE EAST & AFRICA GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 90. EUROPE, MIDDLE EAST & AFRICA GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY METABOLIC DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 91. EUROPE, MIDDLE EAST & AFRICA GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY RARE DISEASES, 2018-2032 (USD MILLION)
  • TABLE 92. EUROPE, MIDDLE EAST & AFRICA GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 93. EUROPE, MIDDLE EAST & AFRICA GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY APPLICATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 94. EUROPE, MIDDLE EAST & AFRICA GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 95. EUROPE, MIDDLE EAST & AFRICA GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 96. EUROPE GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 97. EUROPE GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 98. EUROPE GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY METABOLIC DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 99. EUROPE GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY RARE DISEASES, 2018-2032 (USD MILLION)
  • TABLE 100. EUROPE GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 101. EUROPE GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY APPLICATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 102. EUROPE GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 103. EUROPE GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 104. MIDDLE EAST GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 105. MIDDLE EAST GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 106. MIDDLE EAST GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY METABOLIC DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 107. MIDDLE EAST GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY RARE DISEASES, 2018-2032 (USD MILLION)
  • TABLE 108. MIDDLE EAST GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 109. MIDDLE EAST GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY APPLICATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 110. MIDDLE EAST GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 111. MIDDLE EAST GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 112. AFRICA GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 113. AFRICA GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 114. AFRICA GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY METABOLIC DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 115. AFRICA GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY RARE DISEASES, 2018-2032 (USD MILLION)
  • TABLE 116. AFRICA GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 117. AFRICA GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY APPLICATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 118. AFRICA GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 119. AFRICA GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 120. ASIA-PACIFIC GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 121. ASIA-PACIFIC GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 122. ASIA-PACIFIC GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY METABOLIC DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 123. ASIA-PACIFIC GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY RARE DISEASES, 2018-2032 (USD MILLION)
  • TABLE 124. ASIA-PACIFIC GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 125. ASIA-PACIFIC GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY APPLICATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 126. ASIA-PACIFIC GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 127. ASIA-PACIFIC GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 128. GLOBAL GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 129. ASEAN GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 130. ASEAN GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 131. ASEAN GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY METABOLIC DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 132. ASEAN GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY RARE DISEASES, 2018-2032 (USD MILLION)
  • TABLE 133. ASEAN GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 134. ASEAN GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY APPLICATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 135. ASEAN GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 136. ASEAN GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 137. GCC GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 138. GCC GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 139. GCC GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY METABOLIC DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 140. GCC GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY RARE DISEASES, 2018-2032 (USD MILLION)
  • TABLE 141. GCC GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 142. GCC GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY APPLICATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 143. GCC GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 144. GCC GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 145. EUROPEAN UNION GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 146. EUROPEAN UNION GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 147. EUROPEAN UNION GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY METABOLIC DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 148. EUROPEAN UNION GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY RARE DISEASES, 2018-2032 (USD MILLION)
  • TABLE 149. EUROPEAN UNION GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 150. EUROPEAN UNION GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY APPLICATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 151. EUROPEAN UNION GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 152. EUROPEAN UNION GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 153. BRICS GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 154. BRICS GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 155. BRICS GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY METABOLIC DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 156. BRICS GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY RARE DISEASES, 2018-2032 (USD MILLION)
  • TABLE 157. BRICS GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 158. BRICS GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY APPLICATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 159. BRICS GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 160. BRICS GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 161. G7 GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 162. G7 GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 163. G7 GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY METABOLIC DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 164. G7 GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY RARE DISEASES, 2018-2032 (USD MILLION)
  • TABLE 165. G7 GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 166. G7 GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY APPLICATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 167. G7 GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 168. G7 GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 169. NATO GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 170. NATO GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 171. NATO GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY METABOLIC DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 172. NATO GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY RARE DISEASES, 2018-2032 (USD MILLION)
  • TABLE 173. NATO GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 174. NATO GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY APPLICATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 175. NATO GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 176. NATO GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 177. GLOBAL GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 178. UNITED STATES GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 179. UNITED STATES GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 180. UNITED STATES GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY METABOLIC DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 181. UNITED STATES GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY RARE DISEASES, 2018-2032 (USD MILLION)
  • TABLE 182. UNITED STATES GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 183. UNITED STATES GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY APPLICATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 184. UNITED STATES GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 185. UNITED STATES GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 186. CHINA GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 187. CHINA GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 188. CHINA GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY METABOLIC DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 189. CHINA GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY RARE DISEASES, 2018-2032 (USD MILLION)
  • TABLE 190. CHINA GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 191. CHINA GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY APPLICATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 192. CHINA GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 193. CHINA GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)